Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 6.5% – Should You Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price rose 6.5% during mid-day trading on Thursday . The stock traded as high as GBX 1.20 ($0.02) and last traded at GBX 1.14 ($0.01). Approximately 4,621,293 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 10,060,599 shares. The stock had previously closed at GBX 1.07 ($0.01).

Hemogenyx Pharmaceuticals Stock Performance

The stock has a market capitalization of £15.09 million, a price-to-earnings ratio of -117.80 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The stock has a 50-day moving average of GBX 1.33 and a 200 day moving average of GBX 1.36.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.